The ''Quality Management in Pharma and Biotech'' course, first organized in 1997, has successfully given hundreds of (aspiring) Qualified Persons and other quality professionals a solid basis to fulfill their essential role in the pharmaceutical industry and hospital pharmacies.
Quality Management in Pharma and Biotech (Module 1 to 4)
Four modules offering an integrated approach to quality management in pharma and biotech.
-
Based on 2,089 participants
GMP & GDP training for pharma & biotech
-
Language:
- 13 days in total
This training contains:
Training Dates
This course combines a number of modules that have fixed starting dates. The moment of registration determines which module or course you can attend first.
The modules included in this course are:
-
Quality Management – The Role of the Qualified Person
This training provides insight into an integrated approach on quality management as a good business practice in the pharmaceutical...
-
Quality Management in Drug Development
This training program is designed to equip professionals in the pharmaceutical industry and hospital pharmacies with the...
-
Quality Management in Sterile Manufacturing
The sterility of a pharmaceutical product can only be assured when a series of control measures are in place. The sterility...
-
Quality Management in Biopharmaceutical Manufacturing
Biopharmaceuticals are the next generation of medicines. As they originate from live cells, there are several quality concerns...
It is not required to follow the modules in sequential order.
Description
The Training
Target Audience
If you're a pharmacist or hospital pharmacist interested in earning accreditation points by attending this training,
(University) Students
Results
- Basic qualifications for your Qualified Person (QP) status application after successful completion of all four exams, combined with a relevant university degree.
- Gained a clear overview of the essential quality systems required to improve quality management in your own organization.
- Thorough theoretical and practical knowledge on compliant QP product release, safeguarding the final quality of products administered to patients.
Contents
Course structure
All four modules
Certificates & accreditation
You will receive a certificate of attendance after attending a module. Additionally, you are offered the possibility to achieve full completion of the modules through an examination. In combination with a university degree in, e.g. pharmacy, biology, chemistry or (bio)pharmaceutical sciences, and with relevant practical experience, successful completion of all modules of the training course forms a good starting point to apply for a Qualified Person (QP) status.
PCS will apply for accreditation for each individual module with hospital pharmacists’ professional association NVZA.
Program
| Lecture | ||
|---|---|---|
| Module 1 - Quality Management – The Role of the Qualified Person | Day 1 | ||
|
Introduction: The Roles and duties of the Qualified Person in Pharmaceutical Quality Management
|
||
|
Roadmap to realize Sustainable Quality and Regulatory Compliance Performance (IGJ)
|
||
|
Training, Qualifications and Roles & Responsibilities
|
||
|
Change Control
|
||
|
Deviation & CAPA Management
|
||
|
Complaint handling to recall (QP involvement)
|
||
| Lecture | ||
|---|---|---|
| Module 1 - Quality Management – The Role of the Qualified Person | Day 2 | ||
|
Validation & qualification
|
||
|
QP Skills & Challenges
|
||
|
Trending and Management review and QP involvement
|
||
|
The QP Declaration
|
||
|
API & Excipients
|
||
|
Challenges of a QP in Industry
|
||
|
QP role in Hospital environment
|
||
|
Quality Control and the QP
|
||
|
Out-of-Specification (OOS) including batch decision: release or reject situation
|
||
| Lecture | ||
|---|---|---|
| Module 1 - Quality Management – The Role of the Qualified Person | Day 3 | ||
|
The Critical Impact of Culture and Behavior: Introduction
|
||
|
Lessons from the Case Study Quality Culture & Behaviour
|
||
|
Case Study Presentation and Discussion: Risk Management (as per ICH Q9)
|
||
|
Case Study Presentation and Discussion: Deviation Management
|
||
|
Current regulatory development and inspection highlights (IGJ)
|
||
|
Questions & Answers and Discussion
|
||
| Lecture | ||
|---|---|---|
| Module 1 - Quality Management – The Role of the Qualified Person | Day 4 | ||
|
Case Study Presentation and Discussion: Third Party Operations
|
||
|
Case Study Presentation and Discussion: Data Integrity
|
||
|
MAH responsibilities
|
||
|
The registration dossier - its development and life-cycle
|
||
|
The QP and the registration dossier
|
||
|
Critical points in scaling up (process from development to clinical to commercial)
|
||
|
From R&D lead to development active substance to pharmaceutical formulation
|
||
| Lecture | ||
|---|---|---|
| Module 1 - Quality Management – The Role of the Qualified Person | Day 5 | ||
|
Toxicology & HBEL's
|
||
|
GLP basics
|
||
|
Safety and Pharmacovigilance
|
||
|
Investigational Medicinal Products and the QP
|
||
|
Workshop
|
||
|
End of the training, closing remarks
|
||
| Lecture | ||
|---|---|---|
| Module 2 - Quality Management in Drug Development | Day 6 | ||
|
Welcome, Introduction and Personal Expectations
|
||
|
Introduction to Drug Discovery - From Patient to Target Product Profile (TPP)
|
||
|
The importance of GMP for IMP’s and practical aspects including the role of the QP for IMP
|
||
|
The IMPD and the Registration Dossier
|
||
|
Defining the QTTP, CPP and CQA
|
||
|
QbD, ATP and Validation
|
||
|
Analytical Development
|
||
|
Product Development
|
||
| Lecture | ||
|---|---|---|
| Module 2 - Quality Management in Drug Development | Day 7 | ||
|
Opening and Reflection
|
||
|
Pharmacokinetics and pharmacodynamics (PK/PD)
|
||
|
Pharmacokinetics and pharmacodynamics (PK/PD)
|
||
|
Non-Clinical Studies
|
||
|
GLP & Non-Clinical Studies
|
||
|
GCP & Clinical Trials
|
||
|
From development documentation to IMPD to registration filing
|
||
|
Workshop: Begin with the End in mind!
|
||
|
GCP & Clinical Studies
|
||
|
Reflection, Evaluation & Closure
|
||
| Lecture | ||
|---|---|---|
| Module 3 - Quality Management in Sterile Manufacturing | Day 8 | ||
|
Welcome and outline of the course
|
||
|
Biology of microorganisms
|
||
|
Sterile manufacturing: a philosophy on design and control
|
||
|
Environmental monitoring
|
||
|
Pharmaceutical water systems and utilities
|
||
|
The gowning procedure
|
||
| Lecture | ||
|---|---|---|
| Module 3 - Quality Management in Sterile Manufacturing | Day 9 | ||
|
Sterilization methods: steam, dry heat
|
||
|
Cleaning and desinfection
|
||
|
Sterilization methods: Filtration and alternative methods
|
||
|
Case studies: Sterility Assurance in practice
|
||
|
Contamination Control Strategy
|
||
| Lecture | ||
|---|---|---|
| Module 3 - Quality Management in Sterile Manufacturing | Day 10 | ||
|
Validation of aseptic processes
|
||
|
Aseptic operations in ATMP manufacture
|
||
|
Workshop: the role of the QP in assuring the quality of sterile pharmaceuticals
|
||
|
Evaluation of the course
|
||
| Lecture | ||
|---|---|---|
| Module 4 - Quality Management in Biopharmaceutical Manufacturing | Day 11 | ||
|
Welcome and introduction
|
||
|
Introduction to biotechnology:
|
||
|
Upstream process development for biopharmaceutical products
|
||
|
Protein analytics of biopharmaceuticals: relevant assays and their principles
|
||
|
Quality challenges for Advanced Therapy Medicinal Products (ATMPs)
|
||
| Lecture | ||
|---|---|---|
| Module 4 - Quality Management in Biopharmaceutical Manufacturing | Day 12 | ||
|
Purification survey of unit operations and process integration
|
||
|
Design of an industrial process for purification of biologicals
|
||
|
Development, tech transfer and commercial production of monoclonal antibodies by cell culture – Part 1
|
||
|
Development, tech transfer and commercial production of monoclonal antibodies by cell culture – Part 2
|
||
| Lecture | ||
|---|---|---|
| Module 4 - Quality Management in Biopharmaceutical Manufacturing | Day 13 | ||
|
Cell line development and cell bank preparation
|
||
|
Critical attributes and comparability studies
|
||
|
Immunogenicity and formulation of biopharmaceuticals
|
||
|
Pathogen safety
|
||
|
Biosimilars: a new class of licensed biotech products
|
||
|
Closing Workshop
|
||
|
Evaluation of the course
|
||
Practical Information
- Difficulty / Level:
- Group discounts:
-
- 2 participants - 5%
- 3 participants - 10%
- 4 participants - 15%
- 4 participants - 20%
- 6+ participants - 25%
Group discounts are only applicable when multiple participants register for the same course at the same time.
- Languages throughout the modules:
-
-
English spoken language (primary)
-
Dutch spoken language (secondary)
- Some lectures/lessons may be in the secondary language. The primary language remains the dominant spoken/written language during the training.
-
- Learning form:
- Classroom
- Requires preparation:
-
Yes.
Every module in this series contains homework.
- Includes exam:
- Yes.
- Exam price:
- €1,400.00 ex. VAT per participant.
Tags
Related Courses
GMP for Mid-Level Management in the Pharmaceutical Industry
Based on 963 participants
Annex 1 (Practical Implementation of a Contamination Control Strategy)
Good Writing Practices
Based on 128 participants
GDP for the QP/RP Refresher
Good Distribution Practices (GDP) – also for the Responsible Person (classroom)
Based on 408 participants
External Audits & Self-inspections
Based on 405 participants